Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis

Ende, Tom van den; Veer, Emil ter; Mali, Rosa M A; Henegouwen, Mark I. van Berge; Hulshof, Maarten C.C.M.; Oijen, Martijn G.H. van; Laarhoven, Hanneke W. M. van

doi:10.3390/cancers11040530

Cited by 18 publications

(15 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result may be because OS is affected by many factors, such as late treatment, other diseases. The multivariate analysis indicated that LVI status, as well as N stage and Clinical-Radscorepredicted LVI status, is an independent prognostic factor in GC patients, which is in accordance with previous results of many studies [11,29,30].…”

Section: Discussionsupporting

confidence: 90%

Radiomics analysis of contrast-enhanced CT predicts lymphovascular invasion and disease outcome in gastric cancer: a preliminary study

Chen

Yang

et al. 2020

Cancer Imaging

View full text Add to dashboard Cite

Background: To determine whether radiomics features based on contrast-enhanced CT (CECT) can preoperatively predict lymphovascular invasion (LVI) and clinical outcome in gastric cancer (GC) patients. Methods: In total, 160 surgically resected patients were retrospectively analyzed, and seven predictive models were constructed. Three radiomics predictive models were built from radiomics features based on arterial (A), venous (V) and combination of two phase (A + V) images. Then, three Radscores (A-Radscore, V-Radscore and A + V-Radscore) were obtained. Another four predictive models were constructed by the three Radscores and clinical risk factors through multivariate logistic regression. A nomogram was developed to predict LVI by incorporating A + V-Radscore and clinical risk factors. Kaplan-Meier curve and log-rank test were utilized to analyze the outcome of LVI. Results: Radiomics related to tumor size and intratumoral inhomogeneity were the top-ranked LVI predicting features. The related Radscores showed significant differences according to LVI status (P < 0.01). Univariate logistic analysis identified three clinical features (T stage, N stage and AJCC stage) and three Radscores as LVI predictive factors. The Clinical-Radscore (namely, A + V + C) model that used all these factors showed a higher performance (AUC = 0.856) than the clinical (namely, C, including T stage, N stage and AJCC stage) model (AUC = 0.810) and the A + V-Radscore model (AUC = 0.795) in the train cohort. For patients without LVI and with LVI, the median progression-free survival (PFS) was 11.5 and 8.0 months (P < 0.001),and the median OS was 20.2 and 17.0 months (P = 0.3), respectively. In the Clinical-Radscore-predicted LVI absent and LVI present groups, the median PFS was 11.0 and 8.0 months (P = 0.03), and the median OS was 20.0 and 18.0 months (P = 0.05), respectively. N stage, LVI status and Clinical-Radscore-predicted LVI status were associated with disease-specific recurrence or mortality. Conclusions: Radiomics features based on CECT may serve as potential markers to successfully predict LVI and PFS, but no evidence was found that these features were related to OS. Considering that it is a single central study, multi-center validation studies will be required in the future to verify its clinical feasibility.

show abstract

Section: Discussionsupporting

confidence: 90%

Radiomics analysis of contrast-enhanced CT predicts lymphovascular invasion and disease outcome in gastric cancer: a preliminary study

Chen

Yang

et al. 2020

Cancer Imaging

View full text Add to dashboard Cite

show abstract

“…Tissue-derived or circulating biomarkers have been widely studied, but these data are hardly applicable to the curative setting at the time being. 11 Starting from that, we searched the literature for articles investigating biomarkers in LAGC and 23 articles were finally included in our review. 12–33 The population evaluated in the analysis was homogeneous in terms of clinical setting, since all patients had a gastric or EGJ cancer, received NAC, and underwent radical surgery.…”

Section: Discussionmentioning

confidence: 99%

“…MSI and EBV status have been widely studied, 9,10 but evidence is still heterogeneous and hardly applicable to clinical practice. 11 In addition, the majority of data derived from surgical specimens, often pre-treated with NAC. Ideally, to assess the predictive value of a biomarker to a specific NAC, it should be determined from material obtained before the treatment.…”

Section: Introductionmentioning

confidence: 99%

Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal

et al. 2021

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NAC) significantly improved the prognosis of patients with locally advanced resectable gastric cancer but, despite important progresses, relapse-related death remains a major challenge. Therefore, it appears crucial to understand which patients will benefit from peri-operative treatment. Biomarkers such as human epidermal growth factor receptor-2 (HER2), microsatellite instability (MSI), and Epstein-Barr Virus (EBV) have been widely studied; however, they do not yet guide the choice of perioperative treatment in clinical practice. We performed a narrative review, including 23 studies, addressing the value of tissue- or blood-based biomarkers in the neoadjuvant setting. Ten studies (43.5%) were prospective, and more than half were conducted in East-Asia. Biomarkers were evaluated only post-NAC (on surgical samples or blood) in seven studies (30.4%), only pre-NAC (on endoscopic specimens or blood) in 10 studies (43.5%), and both pre- and post-NAC (26.1%) in six studies. Among the high variety of investigated biomarkers, some of these including MSI-H or enzymatic profile (as TS, UGT1A1, MTHFR, ERCC or XRCC) showed promising results and deserve to be assessed in methodologically sound clinical trials. The identification of molecular biomarkers in patients treated with NAC for locally advanced resectable gastric or EGJ cancer remains crucial.

show abstract

“…In a recent systematic review and meta-analysis, van den Ende et al identified 23 potentially relevant prognostic and 15 predictive factors for the curative treatment of GC ( 28 ).…”

Section: Prognostic Factors In Gc Histology and Molecular Classificat...mentioning

confidence: 99%

Vitamin D modulation and microRNAs in gastric cancer: prognostic and therapeutic role

Martín¹,

Castiñeiras²

2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Gastric adenocarcinoma arises after a complex interaction between the host and environmental factors. Tumor location and TNM are the tools that currently guide treatment decisions. Surgery is the only curative treatment, but relapse is common. After relapse or advanced staged disease survival is poor and systemic treatment has modestly improved survival. An association between sun exposure, vitamin D status and gastric cancer (GC) incidence and mortality has been reported. The molecular differences of the histological subtypes and the new molecular classifications account for the great heterogeneity of this disease and are the basis for the discovery of new therapeutic targets. New prognostic and predictive factors are essential and microRNAs (miRNAs) are endogenous small non-coding RNA molecules with a great potential for diagnosis, prognosis and treatment of cancer. There are hundreds of miRNAs with altered expression in tumor gastric tissue when compared to normal gastric tissue. Many of these miRNAs are associated with clinicopathological variables and survival in patients with GC. Furthermore, the expression of some of these miRNAs with prognostic importance in CG is influenced by vitamin D and others are mediators of some of the actions of this vitamin. This review aims to update the evidence on several miRNAs with prognostic value and therapeutic potential in GC, whose expression may be influenced by vitamin D or may regulate vitamin D signaling.

show abstract

Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis

Cited by 18 publications

References 137 publications

Radiomics analysis of contrast-enhanced CT predicts lymphovascular invasion and disease outcome in gastric cancer: a preliminary study

Radiomics analysis of contrast-enhanced CT predicts lymphovascular invasion and disease outcome in gastric cancer: a preliminary study

Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal

Vitamin D modulation and microRNAs in gastric cancer: prognostic and therapeutic role

Contact Info

Product

Resources

About